Anti-inhibitor coagulant complex is a Blood Derivative owned by Takeda Pharmaceutical, and is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 is planned.

Feiba VH (Anti-Inhibitor Coagulant Complex), is an anti-hemophilic and a blood coagulation factor. The components of the activated prothrombin complex, zymogen prothrombin (F II) and activated Factor X (FXa) play the crucial role in the action of FEIBA. The other zymogens and active enzymes enhance the thrombin generation process on the activated platelet surface thus achieving hemostasis bypassing the requirements of factor VIII (or FIX).

The revenue for Anti-inhibitor coagulant complex is expected to reach a total of $3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Anti-inhibitor coagulant complex NPV Report.

Anti-inhibitor coagulant complex is currently owned by Takeda Pharmaceutical.

Anti-inhibitor coagulant complex Overview

Anti-Inhibitor Coagulant Complex (Feiba VH, Feiba NF, Feiba, Autoplex-T, Feiba S-TIM) is an anti-hemophilic and a blood coagulation factor. It is formulated as powder for solution for intravenous route of administration. It is indicated for the control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and hemophilia B patients with inhibitors.

Takeda Pharmaceutical Overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Anti-inhibitor coagulant complex

Report Segments
  • Innovator (NME)
Drug Name
  • Anti-inhibitor coagulant complex
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.